CD7 and neoplasm: Twelve studies were on T cell malignancies; they KO CD2 [208], CD3 [35, 48], CD5 [138, 150, 177, 178, 198, 206], or CD7 [32, 35, 138, 156, 207] and simultaneously targeted these antigens on tumor cells.